Genetic Signatures Ltd has released a press release.
3base Kit for Antimicrobial Resistance Shows High Detection
Filed with ASX ·
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Genetic Signatures Ltd. on 6ix
Story so far
Earlier from Genetic Signatures
- Full Year Statutory Accounts
- Clinical trial recruitment completed for US enteric kit
- Public Health Wales Awards Enteric Testing Contract to GSS
- S&P DJI Announces March 2022 Quarterly Rebalance
- 3base SARS-CoV-2 kit registered by TGA for saliva samples
Later from Genetic Signatures
- Response to ASX Query
- Influenza B Detection Expected to Impact on Quarter Sales
- FDA 510(k) for Gastrointestinal Parasite Kit Submitted
- 510(k) Filing in Preparation for US Commercial Launch
- Quarterly update and Appendix 4C
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures